Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential

Uterine smooth muscle tumors are the most common female genital tract neoplasms. While leiomyosarcoma has been studied at length, smooth muscle tumors of uncertain malignant potential (STUMPs) still have ambiguous and unresolved issues, with a risk of relapse and evolution largely undefined. We performed an array comparative genomic hybridization analysis on a primitive STUMP and its local recurrence, histologically diagnosed as undifferentiated sarcoma. To the best of our knowledge, our report is the first genomic study on primitive STUMPs and the different relapsed tumors. The results showed few copy number alterations shared between both samples and the high heterogeneity in the STUMP was apparently lost in the sarcoma. Surprisingly the STUMP presented an amplification of the BCL2 gene, not observed in the relapsed tumor. Additionally, fluorescence in situ hybridization and immunohistochemical staining were performed to confirm BCL2 amplification and expression in these samples and in two other cases of primitive STUMPs and their corresponding relapsed tumors. The presence of BCL2 in multiple copies and expression in the two primitive STUMPs and two relapsed tumors was confirmed. The marked amplification of the BCL2 gene present in the primitive STUMP and the multiple copies also observed in other cases, suggest its potential role as a marker of STUMP malignant potential and recurrence.

[1]  H. Galehdari,et al.  Time depended Bcl-2 inhibition might be useful for a targeted drug therapy , 2015, Cancer Cell International.

[2]  N. Seki,et al.  Downregulation of the microRNA-1/133a cluster enhances cancer cell migration and invasion in lung-squamous cell carcinoma via regulation of Coronin1C , 2014, Journal of Human Genetics.

[3]  P. Ghia,et al.  Reprogramming cell death: BCL2 family inhibition in hematological malignancies. , 2013, Immunology letters.

[4]  Dong-rong Yang,et al.  Dual role of TGFBR3 in bladder cancer. , 2013, Oncology reports.

[5]  B. Yamrom,et al.  Rare de novo germline copy-number variation in testicular cancer. , 2012, American journal of human genetics.

[6]  N. Barbetakis,et al.  Uterine smooth muscle tumor of uncertain malignant potential: A rare cause of multiple pulmonary nodules , 2012, Indian Journal of Medical and Paediatric Oncology.

[7]  P. Meltzer,et al.  Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors , 2012, Cell Death and Disease.

[8]  Iman H Hewedi,et al.  Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors , 2012, Diagnostic Pathology.

[9]  M. Valsecchi,et al.  Chromosomal Aberrations in Bladder Cancer: Fresh versus Formalin Fixed Paraffin Embedded Tissue and Targeted FISH versus Wide Microarray-Based CGH Analysis , 2011, PloS one.

[10]  E. Cesarman,et al.  Primary effusion lymphoma: genomic profiling revealed amplification of SELPLG and CORO1C encoding for proteins important for cell migration , 2010, The Journal of pathology.

[11]  Peter Vajkoczy,et al.  Myeloid Zinc Finger 1 Induces Migration, Invasion, and In vivo Metastasis through Axl Gene Expression in Solid Cancer , 2010, Molecular Cancer Research.

[12]  P. Clement,et al.  Uterine Smooth Muscle Tumors of Uncertain Malignant Potential (STUMP):: A Clinicopathologic Analysis of 16 Cases , 2009, The American journal of surgical pathology.

[13]  John Calvin Reed,et al.  Bcl-2 family proteins and cancer , 2008, Oncogene.

[14]  G. Blobe,et al.  The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. , 2007, Cancer research.

[15]  B. Moeller,et al.  The type III TGF-β receptor suppresses breast cancer progression , 2007 .

[16]  Bruce A Luxon,et al.  Genomic profiling identifies alterations in TGFβ signaling through loss of TGFβ receptor expression in human renal cell carcinogenesis and progression , 2003, Oncogene.

[17]  A. Lindblom,et al.  Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. , 2001, Carcinogenesis.

[18]  A. Harris,et al.  Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer. , 1998, British Journal of Cancer.

[19]  C. Angeletti,et al.  Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. , 1995, British Journal of Cancer.

[20]  D. Louis,et al.  Human gliomas with wild-type p53 express bcl-2. , 1995, Cancer research.

[21]  U. Veronesi,et al.  The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. , 1994, Journal of the National Cancer Institute.

[22]  Dong-rong Yang,et al.  Dual role of TGFBR 3 in bladder cancer , 2013 .

[23]  Chen,et al.  Cancer esearch cular and Cellular Pathobiology Mitotic Kinase Aurora-A Induces Mammary l Migration and Breast Cancer Metastasis R ctivating the Cofilin-F-actin Pathway , 2010 .

[24]  T. Nikaido,et al.  Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus , 1999, British Journal of Cancer.